{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:18:46Z","timestamp":1791260326949,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ocular manifestations (OMs) are recognized extraintestinal complications in inflammatory bowel disease (IBD), but their incidence remains understudied. We aimed to evaluate the incidence and trends of OM in a large population-based cohort of adults with newly diagnosed IBD over the past 2 decades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study including all adult-onset IBD patients between 2005 and 2024 in a large health maintenance organization. Patients with pre-existing OM diagnoses were excluded. The primary outcome was incident OM (uveitis, episcleritis\/scleritis, or orbital inflammation) after IBD diagnosis. Annual incidence trends were assessed using the Cochran-Armitage test. Risk factors were analyzed via multivariable Cox regression, stratified by IBD type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 15\u200a035 newly diagnosed IBD patients (51.8% Crohn\u2019s disease [CD], 48.2% ulcerative colitis [UC]), 349 developed an OM over 119\u200a669 person-years (incidence: 2.9 per 1000 person-years; 95% confidence interval [CI], 2.62-3.24). OM incidence was higher in CD than UC (log-rank P &amp;lt; .001) and remained stable over time (P = .125). The median time to OM was 45\u2009months. In CD, female sex (hazard ratio [HR], 1.62; 95% CI, 1.24-2.13) and systemic corticosteroid use (HR, 1.62; 95% CI, 1.18-2.22) were significant risk factors. In UC, corticosteroids (HR, 2.17; 95% CI, 1.40-3.37) and intestinal surgery (HR, 3.50; 95% CI, 1.69-7.28) were associated with increased OM risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OMs in adult-onset IBD are infrequent but clinically relevant, particularly among CD patients and those with markers of severe disease. Clinician awareness and early referral remain essential for prompt diagnosis and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf213","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:35:40Z","timestamp":1756208140000},"page":"220-227","source":"Crossref","is-referenced-by-count":3,"title":["Incidence of Ocular Manifestation After Adult-Onset Inflammatory Bowel Disease: A 20-Year Population-Based Cohort Study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-5271","authenticated-orcid":false,"given":"Henit","family":"Yanai","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, IBD Center, Rabin Medical Center , Petah Tikva,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Achler","sequence":"additional","affiliation":[{"name":"Maccabi Healthcare Services , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ben-Tov","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv,","place":["Israel"]},{"name":"Maccabi Healthcare Services , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-4520","authenticated-orcid":false,"given":"Tali","family":"Sharar Fischler","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, IBD Center, Rabin Medical Center , Petah Tikva,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Patalon","sequence":"additional","affiliation":[{"name":"Maccabi Healthcare Services , Tel Aviv,","place":["Israel"]},{"name":"Arison School of Business, Reichman University , Herzliya,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Gazit","sequence":"additional","affiliation":[{"name":"Maccabi Healthcare Services , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2787-4096","authenticated-orcid":false,"given":"Amit","family":"Assa","sequence":"additional","affiliation":[{"name":"Institute of Pediatric Gastroenterology, Hepatology and Nutrition, Kaplan Medical Center , Rehovot,","place":["Israel"]},{"name":"Hebrew University of Jerusalem , Jerusalem,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Shulman","sequence":"additional","affiliation":[{"name":"Ophthalmology Institute, Assuta Medical Center , Tel-Aviv,","place":["Israel"]},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev , Beer-Sheva,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2026013010473207400_izaf213-B1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ibd\/izad061","article-title":"Prevalence of extraintestinal manifestations in inflammatory bowel disease: a systematic review and meta-analysis","volume":"30","author":"Kilic","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010473207400_izaf213-B2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026013010473207400_izaf213-B3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00054725-200111000-00005","article-title":"Clinical outcome of Crohn\u2019s disease: analysis according to the Vienna classification and clinical activity","volume":"7","author":"Veloso","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010473207400_izaf213-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"Ecco guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026013010473207400_izaf213-B5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"2026013010473207400_izaf213-B6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ecco-jcc\/jjv178","article-title":"Ocular manifestations in inflammatory bowel disease are associated with other extra-intestinal manifestations, gender, and genes implicated in other immune-related traits","volume":"10","author":"Taleban","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2026013010473207400_izaf213-B7","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.3748\/wjg.v17.i22.2702","article-title":"Extraintestinal manifestations of inflammatory bowel disease: Do they influence treatment and outcome?","volume":"17","author":"Veloso","year":"2011","journal-title":"World J Gastroenterol"},{"key":"2026013010473207400_izaf213-B8","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/ibd\/izae160","article-title":"The prevalence and characteristics of inflammatory bowel disease-related ocular involvement in children","volume":"31","author":"Ben-Tov","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010473207400_izaf213-B9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2147\/CLEP.S151339","article-title":"Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an EPI-IIRN group study","volume":"10","author":"Friedman","year":"2018","journal-title":"Clin Epidemiol"},{"key":"2026013010473207400_izaf213-B10","first-page":"655","article-title":"establishing a registry for inflammatory bowel disease patients in maccabi healthcare services\u2014joint project between hospitals, EPI-IIRN group and community medicine]","volume":"157","author":"Kariv","year":"2018","journal-title":"Harefuah"},{"key":"2026013010473207400_izaf213-B11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/ibd\/izae160","article-title":"The prevalence and characteristics of inflammatory bowel disease-related ocular involvement in children","volume":"31","author":"Ben-Tov","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026013010473207400_izaf213-B12","doi-asserted-by":"crossref","first-page":"695904","DOI":"10.3389\/fmed.2021.695904","article-title":"Epidemiology and risk factors in non-infectious uveitis: a systematic review","volume":"8","author":"Joltikov","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026013010473207400_izaf213-B13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ophtha.2022.05.015","article-title":"Association between vaccination with the bnt162b2 mRNA coronavirus disease 2019 vaccine and noninfectious uveitis: a population-based study","volume":"129","author":"Tomkins-Netzer","year":"2022","journal-title":"Ophthalmology"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/2\/220\/64710955\/izaf213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/2\/220\/64710955\/izaf213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:47:40Z","timestamp":1769788060000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/2\/220\/8286834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf213","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,15]]}}}